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Abstract: Ovarian cancer has the highest mortality rate of all gynecological malignancies and the
five-year death rate of patients has remained high in the past five decades. Recently, with the rise
of cancer stem cells (CSCs) theory, an increasing amount of research has suggested that CSCs give
rise to tumor recurrence and metastasis. Theasaponin E1 (TSE1), which was isolated from green
tea (Camellia sinensis) seeds, has been proposed to be an effective compound for tumor treatment.
However, studies on whether TSE1 takes effect through CSCs have rarely been reported. In this
paper, ALDH-positive (ALDH+) ovarian cancer stem-like cells from two platinum-resistant ovarian
cancer cell lines A2780/CP70 and OVCAR-3 were used to study the anti-proliferation effect of TSE1
on CSCs. The ALDH+ cells showed significantly stronger sphere forming vitality and stronger cell
migration capability. In addition, the stemness marker proteins CD44, Oct-4, Nanog, as well as
Bcl-2 and MMP-9 expression levels of ALDH+ cells were upregulated compared with the original
tumor cells, indicating that they have certain stem cell characteristics. At the same time, the results
showed that TSE1 could inhibit cell proliferation and suspension sphere formation in ALDH+ cells.
Our data suggests that TSE1 as a natural compound has the potential to reduce human ovarian
cancer mortality. However, more research is still needed to find out the molecular mechanism of
TSE1-mediated inhibition of ALDH+ cells and possible drug applications on the disease.
Keywords: theasaponin E1; Camellia sinensis; cancer stem cells; ALDH; ovarian cancer
1. Introduction
Ovarian cancer has the highest mortality rate of all gynecological malignancies [1], resulting in
approximately 22,280 new cases being diagnosed and 14,240 deaths occuring every year in the United
States [2]. Around 70% patients fall into relapse and experience chemo-resistance, and the five-year
survival rate remains less than 40% [3]. Recently, with the rise of cancer stem cell (CSCs) theory,
increasingly more research results have shown that CSCs have typical stem cell characteristics,
such as self-renewal, multidifferentiation, and tumorigenicity etc., [4]. CSCs have been confirmed
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and isolated in various solid tumors, such as breast cancer [5], ovarian cancer [6], pancreas cancer [7],
colon cancer [8] and acute myeloid leukemia [9]. Meanwhile, increasingly more studies have suggested
that CSCs contribute to tumor growth, metastasis, chemo-resistance and recurrence with the neoplasm
renewal source. In addition, the existence of CSCs is also a key reason for the failure of conventional
tumor treatments [10]. Thus far, the biomakers including CD44, CD133, CD117, CD24 and aldehyde
dehydrogenase (ALDH) have been extensively studied to differentiate and identify CSCs [1,6].
Among these, studies suggest that ALDH may be involved in the epithelial-mesenchymal transition of
tumor cells, allowing cancer cells to evade T-cell-mediated cytolysis, and contributing to the oxidation
of retinol to retinoic acid in early stem cell differentiation [11]. At present, ALDH+ cells exhibited
tumorigenic and chemo-resistance capacity, and proved to be associated with poor patient outcome in
high-grade serous ovarian cancer [6].
Selectively targeting CSCs is a new strategy for tumor treatment. At the same time,
natural compounds have received increasing attention in the research of cancer and CSCs due to
their high activity and low number of side effects. The saponins from Rhizoma paridis have shown
the inhibitory effect on growth of CSCs in non-small cell lung cancer [12]. EGCG and TFs can inhibit
the self-renewal capacity of prostate CSCs, in part by downregulating Bmi1 gene expression [13].
Theasaponin E1 (TSE1), an acylated oleanene-type triterpene ologoglycoside with the molecular
formula C59H90O27, was firstly isolated from green tea [Camellia sinensis (L.) O. Kuntze] seeds in
1998 [14]. This compound has been proven to possess various activities. TSE1 could alleviate the salt
tolerance of yeasts [15], and inhibit ethanol-induced gastric mucosal lesions [16], angiogenesis and
obesity [17]. It could also suppress the human tumor cell lines K562 and HL60 [18]. Our previous
study showed that the total saponins from C. sinensis seeds exhibit potent growth inhibitory effect on
two cisplatin-resistant ovarian cancer cell lines A2780/CP70 and OVCAR-3 [19].
In this study, A2780/CP70 and OVCAR-3 cell lines were chosen. The tumor sphere culture
method was selected to accumulate CSCs. ALDH was used as a stem cell surface marker to indirectly
detect the proportion of CSCs. TSE1 was selected as the experimental drug. The purpose is to detect
the population of ALDH+ cells that were accumulated in two ovarian cancer cell lines and determine if
those cells have certain stem cell characteristics, then investigate the effect of TSE1 on the ALDH+ cells.
2. Results
2.1. Expression of ALDH in Both Tumor and Sphere Cells
According to the basic principle of serum-free culture, the differentiated mature tumor cells cannot
adhere to the wall and go to apoptosis in the serum-free state, whereas undifferentiated CSCs within
total tumor cells can grow and experience multidifferentiation into both tumor and CSCs to form
a spherical aggregate state, thus differentiating from each other. The spheres derived from A2780/CP70
and OVCAR-3 cells appeared and completely formed within seven days (one week). It can be seen in
Figure 1a that two ovarian cancer cells exhibit spindle or oval-shaped single cell distribution in the
adherent culture, but, in the serum-free culture state, both cells showed different degrees of spherical
dense multicellular aggregation and were able to float in the culture fluid. The results indicated the
presence of CSCs in both ovarian cancer cells. An ALDEFLUOR Stem Cell Identification Kit was used
to examine the proportion of ALDH+ cells in the tumor and different culture algebraic suspension cells.
The experimental results showed (Figure 1b) that ALDH+ cells ratio was 1.05%, 5.75%, 12.20% and
29.50% in tumor cells and sphere cells with 1-week, 2-weeks and 3-weeks in A2780/CP70, and 1.25%,
2.75%, 7.20%, 24.95% in OVCAR-3, respectively. Our results indicated that there was indeed a very
small amount of ALDH+ cells in both ovarian cancer cells, which was less than 2.0%, while the
proportion of ALDH+ cells in two cell lines showed a significant increase trend in a time-dependent
manner. In addition, the increasing trend of the A2780/CP70 cell line and the proportion of ALDH+
cells were higher than that of OVCAR-3. The proportion of ALDH+ cells in both of the suspension
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spheres after three generations of culture exceeded 20%, indicating that the serum-free suspension
culture method can significantly enrich CSCs, and is a simple and effective enrichment method.
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were the period of rapid spheres formation, and aggregated spherical cell clusters of different sizes 
appeared in the visual field. From the fifth day to the seventh day, contact between adjacent cell 
masses forming a larger cell mass can only be included once in the count, which was probably the 
reason for the decrease in the number of sphere cells. Another interesting phenomenon was that, on 
the sixth or seventh day, we observed that the cell cluster appeared with black shadows, the cell 
contours became blurred, and a single cell “escape” phenomenon appeared at the edge of the 
spherical cells. We inferred that it may be caused by the migration of cells to a more favorable 
environment in the harsh environment of dense spherical cells in the absence of oxygen and nutrient 
delivery. To confirm whether ALDH+ cells have a stronger ability to metastasize and invade, we 
conducted Transwell chamber experiments and screened ALDH+ cells (three generation) as follow-
up study subjects. The above results demonstrated that ALDH+ cells, especially third-generation cells, 
Figure 1. The population of ALDH of both tumor and sphere cells cultured in serum-free medium
with different weeks from A2780/CP70 and OVCAR-3 cell lines. (a) morphological photographs of
ovarian tumor and sphere cells (3-weeks) for both two cell lines (200×); (b) ALDH ratio after culturing
in serum-free medium could accumulate in a time-dependent manner. Data was expressed as percent
of ALDH+ cells and shown as mean ± SD (n = 3), * = p ≤ 0.05, a significant difference compared with
zero-time control.
2.2. Sphere Cells Exhibits Stemness Properties
The single cell sphere formation ability experimental results showed (Figure 2a) that the average
number of suspended spheres after one week culturing of tumor cells (0 generation) was only about 10.
From the first generation to the third generation of suspension cells, the average number of suspended
spheres increased significantly after one week of culture, indicating that the proportion of ALDH+
cells was positively correlated with the single cell pelleting ability. Observing the number of spheres
of different generations of cells in different cultures on the same day, the same rule was found, and,
in particular, the ability of the third generation cells was significantly increased. It was confirmed that
ALDH+ cells have stronger single-cell spherule ability, and this ability increases as the proportion of
ALDH+ cells increases. Interestingly, the secon -ge eration, third-generatio cells showed a trend of
firstly increased and th n a st ble or slightly decr as d number of spheres which is different from the
trend of zer generation in the control group. Fur hermore, we used A2780/CP70 cells as an example to
observe the state of cell growth and the state of sphere formation daily under a microscope (Figure 2b).
Day 0 cells presented a single cell suspension state. From the first day, it can be observed that some
cells show a globular aggregation, two or three or four cells in a cluster or linear or spherical state
states can be found in the field of vision; the second, third and fourth days were the period of rapid
spheres formation, and aggregated spherical cell clusters of different sizes appeared in the visual field.
From the fifth day to the seventh day, contact between adjacent cell masses forming a larger cell mass
can only be included once in the count, which was probably the reason for the decrease in the number
of sphere cells. Another interesting phenomenon was that, on the sixth or seventh day, we observed
that the cell cluster appeared with black shadows, the cell contours became blurred, and a single cell
“escape” phenomenon appeared at the edge of the spherical cells. We inferred that it may be caused b
the migration of cells to a more favorable environment in t e harsh env ronment f dense spheric l
cells in the absence of oxygen and nutrient delivery. To confirm whether ALDH+ cells have a stronger
ability to metastasize and invade, we conducted Transwell chamber experiments and screened ALDH+
cells (three generation) as follow-up study subjects. The above results demonstrated that ALDH+ cells,
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especially third-generation cells, have stronger capabilities than tumor mother cells, which can be used
as a manifestation of the characteristics of cancer stem cells.
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Figure 3. Sphere cells (3-weeks) from A2780/CP70 and OVCAR-3 cell lines possess the stemness
properties. (a) the number of cells through the membrane was observed under a light microscope after
Transwell for migration and invasion assays (100×); (b) both A2780/CP70 and OVCAR-3 sphere cells
had significantly enhanced migration ability, and higher invasion viability only for A2780/CP70 cell
line but not OVCAR-3. Data was expressed as number of spheres and shown as mean ± SD (n = 5),
* = p ≤ 0.05, significant difference compared with tumor cells.
Western blot analysis showed in Figure 4, the expression levels of stemness marker proteins
CD44, Nanog, and Oct-4 in ALDH+ cells were significantly higher than those in tumor cells for both
cell lines. In addition, the expression level of key proteins found to be over-expressed frequently
existed in cancer stem cells, and anti-apoptotic protein Bcl-2, Notch-1 and MMP-9 were detected to
increase in different degrees. Bcl-2 protein was significantly increased in both cells, Notch-1 protein
was significantly changed in OVCAR-3 cells, but not in A2780/CP70 cells. Observing the expression of
MMP-9 protein, both ALDH+ cells were significantly increased, which was consistent with the result
of the cell migration ability detected by Transwell chamber assay. At the same time, we compared the
A2780/CP70 and OVCAR-3 cells, both in tumor and ALDH+ cells, finding that the expression level of
MMP-9 protein was higher in A2780/CP70 than OVCAR-3 cells. This result was also consistent with
Transwell’s results. The above results indicated that ALDH+ cells exhibit certain stem cell biological
characteristics from the molecular level.






Figure 4. Sphere cells (3-weeks) from A2780/CP70 and OVCAR-3 cell lines possess the stemness 
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(b) both A2780/CP70 and OVCAR-3 sphere cells had marked higher expression of CD44, Nanog, Oct-
4, Bcl-2 and MMP-9 proteins compared with tumor cells. Data was expressed as the number of spheres 
and shown as mean ± SD (n = 3), * = p ≤ 0.05. 
2.3. TSE1 Inhibits the Cell Growth of Sphere Cells 
To investigate the anti-proliferation effect of TSE1 on both ALDH+ cells, we firstly observed the 
change of cell morphology under microscope after treatment of different concentrations of TSE1. As 
shown in Figure 5a, with the same treatment time, the number and size of suspended cells showed a 
tendency to decrease with increasing drug concentration. The same trend of action occurred for all 
three treatment times, showing a dose-dependent manner of the inhibitory effect of TSE1. While 
under the same drug concentration treatment, there was no obvious increasing trend in inhibitory 
effect within the prolonged action time. At low concentration of 5 µM, TSE1 had no effect on ALDH+ 
cells. Under the treatment of 10 µM TSE1, the size and number of suspended spheres were decreased 
to a certain extent. When the concentrations of TSE1 increased to 20 µM or 40 µM, its inhibitory effects 
on the formation size and number of suspended spheres were more pronounced. 
Furthermore, the results of the cytotoxicity assay (MTS method) analysis were consistent with 
the observation of the growth tendency of the suspended spheres (Figure 5b). The viability of 
A2780/CP70 cells ranged from 95.31% to 51.92% at 24 h, from 95.62% to 15.06% at 48 h, and from 
91.54% to 10.13% at 72 h. For the OVCAR-3 cell line, the viability was 102.56% to 47.99% at 24 h, 
100.91% to 20.02% at 48 h, and 93.01% to 12.30% a 72 h. In addition, 5 µM TSE1 had no obvious effect 
on viability, even if the duration of action was extended to 72 h. With the increase of drug 
concentration, the inhibitory activity of TSE1 on ALDH+ cells was significantly increased, and the 
action time had a certain enhancement effect. When the concentration reached to 40 µM, prolonging 
Figure 4. Sphere cells (3-weeks) from A2780/CP70 and OVCAR-3 cell lines possess the stemness
properties. (a) the results of protein strips of CD44, Nanog, Oct-4, Bcl-2, Notch-1 and MMP-9 proteins;
(b) both A2780/CP70 and OVCAR-3 sphere cells had marked higher expression of CD44, Nanog, Oct-4,
Bcl-2 and MMP-9 proteins compared with tumor cells. Data was expressed as the number of spheres
and shown as mean ± SD (n = 3), * = p ≤ 0.05.
Taken together, our findings indicated that ALDH+ cells (3-weeks) accumulated with serum-free
culture have certain biological characteristics of CSCs, and can be considered as ovarian cancer
stem-like cells for follow-up experiments.
2.3. TSE1 Inhibits the Cell Growth of Sphere Cells
To investigate the anti-proliferation effect of TSE1 on both ALDH+ cells, we firstly observed
the change of cell morphology under microscope after treatment of different concentrations of TSE1.
As shown in Figure 5a, with the same treatment time, the number and size of suspended cells showed
a tendency to decrease with increasing drug concentration. The same trend of action occurred for all
three treatment times, showing a dose-dependent manner of the inhibitory effect of TSE1. While under
the same drug concentration treatment, there was no obvious increasing trend in inhibitory effect
within the prolonged action time. At low concentration of 5 µM, TSE1 had no effect on ALDH+ cells.
Under the treatment of 10 µM TSE1, the size and number of suspended spheres were decreased to
a certain extent. When the concentrations of TSE1 increased to 20 µM or 40 µM, its inhibitory effects
on the formation size and number of suspended spheres were more pronounced.
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In view of the MTS results, the ability of TSE1 to inhibit the proliferation of ALDH+ cells was 
achieved by inhibiting the size and number of the cell spheres. We further investigated whether TSE1 
affects the ability of CSCs single cell to pellet. Figure 6 showed that TSE1 exhibited a similar trend for 
ALDH+ cells in two cell lines. At low concentrations of 5 μM and 10 μM TSE1, the number of single 
cells pelleted was not significantly different from that of the control group even when the action time 
was extended from 24 h to 72 h, indicating that low concentration had no effect on the single cell 
pelleting ability of ALDH+ cells, and the action time has no obvious effect on it. With the increase of 
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Fig re 5. E fects of TSE1 on cell growth of spher cells (3-weeks) from A2780/CP70 and OVCAR-3
cell lines. (a) cell morphol gy observation aft r reatmen with various o centrations of TSE1 for 24,
48 and 72 h, respectively, via fluorescent microscopy (1 0×); (b) TSE1 inhibited cell viability of sphere
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Furthermore, the results of the cytotoxicity assay (MTS method) analysis were consistent with the
observation of the growth tendency of the suspended spheres (Figure 5b). The viability of A2780/CP70
cells ranged from 95.31% to 51.92% at 24 h, from 95.62% to 15.06% at 48 h, and from 91.54% to 10.13%
at 72 h. For the OVCAR-3 cell line, the viability was 102.56% to 47.99% at 24 h, 100.91% to 20.02% at
48 h, and 93.01% to 12.30% a 72 h. In addition, 5 µM TSE1 had no obvious effect on viability, even if the
duration of action was extended to 72 h. With the increase of drug concentration, the inhibitory activity
of TSE1 on ALDH+ cells was significantly increased, and the action time had a certain enhancement
effect. When the concentration reached to 40 µM, prolonging the action time can significantly enhance
the inhibitory effect of TSE1. The overall detection analysis was consistent with the observed cell
morphology results. It was complemented that TSE1 could inhibit ALDH+ cells in a dose-dependent
manner. The action time could enhance this inhibition to a certain extent, but it was not the main
influence factor.
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2.4. TSE1 Suppresses the Sphere Formation of Sphere Cells
In view of the MTS results, the ability of TSE1 to inhibit the proliferation of ALDH+ cells was
achieved by inhibiting the size and number of the cell spheres. We further investigated whether TSE1
affects the ability of CSCs single cell to pellet. Figure 6 showed that TSE1 exhibited a similar trend
for ALDH+ cells in two cell lines. At low concentrations of 5 µM and 10 µM TSE1, the number of
single cells pelleted was not significantly different from that of the control group even when the action
time was extended from 24 h to 72 h, indicating that low concentration had no effect on the single cell
pelleting ability of ALDH+ cells, and the action time has no obvious effect on it. With the increase
of TSE1 treatment concentration to 20 µM, the percentage of single cell pellets showed a significant
decreasing trend under three action times, and the prolonged action time could enhance this effect
to some extent, but there was no significant difference among them. When the concentration of TSE1
continued to increase to 40 µM, the inhibitory effect of TSE1 continued to increase, but the action time
still had no significant effect. These results indicated that TSE1 can dose-dependently reduce the single
cell pelleting ability of ALDH+ cells. This result was consistent with the MTS results.
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ovarian cancer [6]. Higher protein levels of CD44, Nanog and Oct-4 observed in this study were
inconsistent with the previous reports, indicating that the ALDH+ cells had some stemness properties.
Moreover, antiapoptotic factor Bcl-2 and the migration related protein MMP-9 were significantly
increased in ALDH+ cells compared with ALDH− tumor cells. Researchers have demonstrated that
the Bcl-2 protein family plays an essential role in regulating intrinsic or mitochondrial apoptosis, and
is strongly associated with drug resistance [25]. Over-expression of Bcl-2 protein has been observed
in side population cells from high grade ovarian cancer [26]. In addition, MMP-9 plays an important
role in the cell metastasis and invasion [27] and contributes to the ovarian tumor aggression and
recurrence [22,28]. The observed over-expressed stemness markers could explain the significantly
enhanced migration activity of ALDH+ cells from both the cell lines and the increased invasion
ability of A2780/CP70 cell line. Overall, our data suggested that ALDH+ cells possessed some cancer
stem cell-like properties including enhanced sphere formation, stronger migration ability and higher
expression of stemness markers.
The saponins have been found to have numerous pharmacological effects including anti-fungal [29],
anti-viral [30], anti-inflammatory [31], anti-hyperlipidemic [32], immunomodulatory [33] and
anti-tumor activities [17,19]. Among these, TSE1 was proved to have higher bioactivity than other
saponin monomers present in tea seeds [17]. Researchers have shown that TSE1 expressed an inhibitory
effect on ethanol-induced gastric mucosal lesions at a dose of 5.0 mg/kg [16]. TSE1 showed significant
quinone reductase (QR) inducing activity at 4 µg/mL (3.25 µM) and could be used as an anti-tumor
agent and a chemo-prevention agent of cancer [18]. Treating with a 10 µg/mL (8.13 µM) concentration
of TSE1 completely inhibited tube formation in human umbilical vein endothelial cells, as well as
TSE1 showing toxicity toward cancer cells and inhibiting in vivo growth of the tumor [17]. On the
other hand, we carried out another study before this work, data showed the estimated half-maximal
inhibitory concentration (IC50) of TSE1 for A2780/CP70 and OVCAR-3 tumor cells were 3.46 µM
and 3.28 µM, respectively. Our results were consistent with those reported data. While the IC50
value of TSE1 for normal ovarian surface epithelial cell line IOSE-364 was 23.82 µM, TSE1 showed
a much lower cytotoxic effect against normal ovarian epithelial cells. In addition, our published data
showed that the IC50 values of cisplatin, which is the most effective and widely used chemotherapeutic
agent, were 11.91 µg/mL (35.71 µM) for A2780/CP70 and 10.10 µg/mL (30.30 µM) for OVCAR-3,
respectively [19]. All data taken together, we indicated that TSE1 exhibited higher inhibitory effects
compared to cisplatin. However, few reports have been published to identify the beneficial biological
activities of TSE1 on CSCs. In this study, we used ALDH+ cells with stemness properties as CSCs model
to demonstrate the TSE1-mediated suppression on CSCs growth and sphere formation. Our results
indicated that TSE1 had significant inhibitory activity against ALDH+ cells of A2780/CP70 and
OVCAR-3 cell lines at concentrations of 20 and 40 µM, but exhibited little influence on both cell lines
at lower concentrations of 5 or 10 µM. The present work indicated that higher TSE1 concentration was
needed to inhibit ALDH+ cells with chemo-resistance capacity [6]. TSE1 decreased numbers of spheres
and cell viability at higher concentrations. As reported, side population cells from high grade ovarian
cancer showed high resistance to chemotherapy drugs, and high survival rate and high potential
to form tumor spheres [26]. The inhibitory effects of TSE1 on cell proliferation and sphere-forming
viability has certain significance to suppress cancer stem cells. However, while increasing TSE1
concentrations impacted the results, increasing the treatment times did not have significant effects.
These results coincide with previous research showing that the cytotoxic effects of saponins on
various cancer cell lines varied based on the type of cell line and on the concentration of saponins [34].
This research also added other evidence to previous research, which demonstrates the anti-proliferative,
anti-tumor and cytotoxic effects of TSE1 [17,18]. These results suggest that TSE1 is a natural and potent
drug candidate for ovarian cancer treatment. However, the molecular weight of tea saponin is 1230,
which is much higher than cisplatin (the molecular weight is 300). Thus, the measurement of the
bioavailability of TSE1 is very valuable for anti-tumor research and possible drug applications for the
disease, as well as the molecular mechanism of TSE1-mediated inhibition of ALDH+ cells.
Molecules 2018, 23, 1469 10 of 14
4. Materials and Methods
4.1. General Experimental Procedures
TSE1 (Figure 7) was purchased from Yingshili Biotechnology (Hangzhou, Zhejiang, China),
and was dissolved in dimethyl sulfoxide (DMSO) at 100 mM and stored at −20 ◦C PLT, 6-well
plates, 24-well plates, 96-well plates, Transwell chambers and Corning Matrigel Basement Membrane
Matrix High Concentration were from Corning (Corning, NY, USA). Aqueous One Solution Cell
Proliferation assay (MTS) was purchased from Promega Corporation (Madison, WI, USA). RPMI-1640
medium was purchased from Sigma-Aldrich (St. Louis, MO, USA). Fetal bovine serum (FBS) was from
Invitrogen (Grand Island, NY, USA). ALDEFLUOR Stem Cell Identification Kit, MammoCult Medium
Human Kit, Hydrocortisone Stock Solution, 0.2% Heparin Solution and HBSS were obtained from
Stem Cell Technologies (Vancouver, BC, Canada). Primary antibodies for Oct-4, CD44, Nanog, Bcl-2,
Notch-1, MMP-9 and horseradish peroxidase-conjugated secondary antibody were purchased from
Cell Signaling Technology, Inc. (Danvers, MA, USA). Antibody for GAPDH was obtained from Santa
Cruz Biotechnology, Inc. (Dallas, TX, USA).
Molecules 2018, 23, x FOR PEER REVIEW  10 of 14 
 
w re obtained from Stem Cell Technologies (V ncouver, BC, Canada). Primary antibodies for O t 4  
CD44, Nanog, Bcl-2, Notch-1, MMP-9 and horseradish peroxi ase-conjugated secondary antib dy 
were purchased from Cell Signali g Technology, Inc. (Danvers, M , USA). Antibody fo  GAPDH 
was obtained fr m Santa Cruz Biotechnology, Inc. (Dallas, TX, USA).  
 
Figure 7. Chemical structure of theasaponin E1. 
4.2. Cell Culture 
Human platinum-resistant ovarian cancer cell lines A2780/CP70 (p53 wild-type) and OVCAR-3 
(p53 mutant) regarded as a gift were kindly provided by Dr. Jiang at West Virginia University. All 
cells were cultured in RPMI-1640 medium supplemented with 10% FBS in a humidified incubator 
with 5% CO2 at 37 °C. Then, cells were subsequently treated through tumor sphere culture for a 
certain time adjusted by each experiment. 
4.3. Tumor Sphere Culture 
This progress was performed under serum-free medium and ultra-low adherent conditions 
according to the manufacturer’s instructions. Briefly, both A2780/CP70 and OVCAR-3 ovarian cancer 
cells (tumor cells) were collected when 70% density was achieved and then suspended into the 
complete mammoculTM medium (complete medium below) supplemented with 4 μg/mL (final 
concentration) 0.2% Heparin Sodium Salt and 0.48 μg/mL (final concentration) Hydrocortisone Stock 
Solution. Cells were seeded at a density of 6,000 cells/well in 6-well ultra-low attachment plates, then 
cultured for 7 days at 37 °C in a humidified incubator with 5% CO2, and visualized under a light 
microscope every day. The spheres were harvested after 7 days of culture for subsequent tumor 
sphere culture using the same method described, and subsequent assays. 
4.4. ALDEFLUORTM Kit ALDH Analysis 
The population of ALDH in tumor and sphere cells (1-week, 2-weeks and 3-weeks) were 
analyzed by a ALDEFLUOR Stem Cell Identification Kit according to the manufacturer’s instructions. 
All cells were harvested from dishes with Trypsin-EDTA, then suspended using ALDEFLUORTM 
Assay Buffer to prepare samples with a density of 106 cells/mL. Then, 1 mL sample was added into a 
test tube with 5 μL activated ALDEFLUORTM Reagent and mixed rapidly. Next, 0.5 mL mixture was 
transferred to the control tube with an added 5 μL ALDEFLUORTM DEAB Reagent prior. All test and 
control samples were mixed quickly, and then cultured for 45 min at 37 °C in a humidified 
atmosphere. Then, all samples were centrifuged at 250× g for 5 min at 4 °C and suspended in 0.5 mL 
ALDEFLUORTM assay buffer. All samples were stored on ice before detection. Finally, all samples 
were filtered through a 40 μm cell trainer to obtain single suspension cells for analysis on a FACSAria 
Ш Flow cytometer (BD). 
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4.2. Cell Culture
Human platinum-resistant ovarian cancer cell lines A2780/CP70 (p53 wild-type) and OVCAR-3
(p53 mutant) regarded as a gift were kindly provided by Dr. Jiang at West Virginia University. All cells
were cultured in RPMI-1640 medium supplemented with 10% FBS in a humidified incubator with
5% CO2 at 37 ◦C. Then, cells were subsequently treated through tumor sphere culture for a certain
time adjusted by each experiment.
4.3. Tumor Sphere Culture
This progress was performed under serum-free medium and ultra-low adherent conditions
according to the manufacturer’s instructions. Briefly, both A2780/CP70 and OVCAR-3 ovarian cancer
cells (tumor cells) were collected when 70% density was achieved and then suspended into the complete
mammoculTM medium (complete medium below) supplemented with 4 µg/mL (final concentration)
0.2% Heparin Sodium Salt and 0.48 µg/mL (final concentration) Hydrocortisone Stock Solution.
Cells were seeded at a density of 6,000 cells/well in 6-well ultra-low attachment plates, then cultured
for 7 days at 37 ◦C in a humidified incubator with 5% CO2, and visualized under a light microscope
every day. The spheres were harvested after 7 days of culture for subsequent tumor sphere culture
using the same method described, and subsequent assays.
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4.4. ALDEFLUORTM Kit ALDH Analysis
The population of ALDH in tumor and sphere cells (1-week, 2-weeks and 3-weeks) were analyzed
by a ALDEFLUOR Stem Cell Identification Kit according to the manufacturer’s instructions. All cells
were harvested from dishes with Trypsin-EDTA, then suspended using ALDEFLUORTM Assay
Buffer to prepare samples with a density of 106 cells/mL. Then, 1 mL sample was added into a test
tube with 5 µL activated ALDEFLUORTM Reagent and mixed rapidly. Next, 0.5 mL mixture was
transferred to the control tube with an added 5 µL ALDEFLUORTM DEAB Reagent prior. All test
and control samples were mixed quickly, and then cultured for 45 min at 37 ◦C in a humidified
atmosphere. Then, all samples were centrifuged at 250× g for 5 min at 4 ◦C and suspended in 0.5 mL
ALDEFLUORTM assay buffer. All samples were stored on ice before detection. Finally, all samples
were filtered through a 40 µm cell trainer to obtain single suspension cells for analysis on a FACSAria
III Flow cytometer (BD).
4.5. Sphere Formation Assay
Tumor and sphere cells (1-week, 2-weeks and 3-weeks) were harvested, then lightly centrifuged at
250× g for 5 min at room temperature, and resuspended using complete medium. All cells were plated
at a density of 100 cells/well in 96-well ultra-low adherent plates, and cultured for a subsequent 7 days
in a humidified incubator containing 5% CO2 at 37 ◦C. The cells were visualized and the number
of spheres (>50 µm) formed were counted [27] under a light microscope every day. All data were
collected from six independent trials to determine the inhibition effect of sphere formation by TSE1.
Sphere cells (3-weeks) were harvested and seeded under the same condition, and cultured for 24 h.
Then, cells were treated with various concentrations of TSE1 (0 to 40 µg/mL) for 24, 48 and 72 h.
The control group received only an equal amount of complete medium. Then, the number of spheres
was counted as above. All data were collected from five independent experiments
4.6. Western Blot Analysis
Ovarian cancer cells were seeded and incubated overnight until 70% density was achieved.
Sphere cells (3-weeks) were collected after 7 days of culture. All cells were centrifuged at 350× g for
5 min at 4 ◦C to remove the old medium. After a double wash with cold PBS, cells were lysed in
50 µL M-PER Mammalian Protein Extraction Reagent supplemented with 1 µL HaltTM Protease and
Phosphatas Inhibitor. Total protein levels were determined by a BCA Protein Assay Kit. The cell lysates
were separated by SDS-PAGE and blotted onto a nitrocellulose membrane with a Mini-Protean 3 System
(Bio-Rad, Hercules, CA, USA). Membranes were blocked with 5% non-fat milk (dissolved in Tris-buffer
saline supplemented with 0.1% Tween 20 (TBST)) for 1 h at room temperature. Then, the membranes
were incubated with specific primary antibodies and secondary antibody dilutions. After washing
with TBST in triplicate, the antigen-antibody complex was visualized with ECL Kit. Protein bands
were quantified with NIH Image J software (version, NIH, Bethesda, MD, USA), and normalized by
corresponding GAPDH bands for analysis.
4.7. Transwell Migration and Invasion Assays
In addition, 50 µL 1/8 dilution of matrigel was seeded into upper Transwell chambers and
solidified in a humidified incubator at 37 ◦C for 30 min to firm membrane for subsequent invasion
assay. Both A2780/CP70 and OVCAR-3 tumor and sphere cells (3-weeks) in suspension serum-free
medium were plated into the upper chambers at 2 × 105 cells/well for invasion assay, and migration
assay without matrigel membrane. A complete medium containing 20% FBS was added to the lower
chamber and incubated for another 24 h. The medium was wiped in the upper chambers and washed
with PBS twice at room temperature. A cotton swab was used to gently wipe out the residual solution
and then crystal violet staining cells were passed through the membrane and attached to the lower
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layer of the membrane for at least 15 min after formaldehyde fixing cells for 15 min. Graphics of cells
that migrated or invaded were taken using wide-field microscopy.
4.8. Cell Viability
Cell growth inhibition was determined by using MTS assay as described as before [19]. Sphere cells
(3-weeks) were seeded into 96-well ultra-low adherent plates at a density of 2000 cells/well in complete
medium for 24 h. Then, cells were treated with various concentrations of TSE1 (0 to 40 µg/mL) for
24, 48 and 72 h at 37 ◦C in a humidified 5% CO2 incubator. The control group received only an equal
amount of complete medium. Then, morphologic observation for spheres was carried out under a light
microscope before cell viability analysis. For MTS assay, 100 µL of MTS was added to each well and
incubated in the dark at 37 ◦C for 1 h. The absorbance was measured at 490 nm with a microplate
reader. Cell viability was expressed as the percentage compared to the untreated group. All data was
collected from five independent experiments.
4.9. Statistical Analysis
In this study, the experiments were performed at least three times. Average values of replicates
were collected and analyzed by one-way analysis of variance (ANOVA) in SPSS 23.0 (Manufacturer, City,
US State abbrev. if applicable, Country). Significant differences between individual treatments and control
were evaluated using Duncan’s test. * = p ≤ 0.05 was considered statistically significant.
5. Conclusions
In this work, the data showed that a rare population of CSCs (less than 2.0%) existed in
A2780/cp70 and OVCAR-3 cell lines and CSCs were noticeably accumulated through serum-free
spheroid formation assay. Most importantly, we demonstrated that ALDH+ cells performed stronger
single cell sphering and migration ability, and demonstrated over-expression of stemness marker
proteins CD44, Nanog and Oct-4, and cancer stem cell-associated proteins Bcl-2 and MMP-9,
thus indicating some biological characteristics of cancer stem cells, which can be considered as
ovarian cancer stem-like cells. In addition, we indicated that TSE1 dose-dependently inhibited the
proliferation and single cell sphere formation ability, though it was not significantly changed by action
time. This study provided new evidence for the anti-tumor activity of TSE1. We suggest that TSE1 has
potential application for use in chemotherapy options to treat advanced ovarian cancer efficiency in
the future. More research should be aimed at the underlying molecular mechanisms of TSE1-mediated
suppression ability on ALDH+ cells for better utility of natural compound of TSE1 in tumor therapy.
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